SentreHEART, Inc., a Redwood City, CA-based medical device company, closed a $35m Series D financing.
The round was led by Deerfield Management Company, with participation from existing investors U.S. Venture Partners, Prospect Ventures, Vivo Capital and Decheng Capital. In conjunction with the funding, Deerfield Partner Ted Huber will join SentreHEART’s Board of Directors.
Founded in 2005 and led by Russ Seiber, CEO and President, SentreHEART has developed technology for remote delivery of suture for closure of anatomic structures including The LARIAT Suture Delivery Device, which is indicated for suture placement and knot tying in surgical procedures where soft tissues are being approximated and/or ligated with a pre-tied polyester suture.
The company, which received FDA 510(k) clearances for the LARIAT in 2006, 2009 and 2014 and CE Mark approval in Europe, intends to use the proceeds to complete the aMAZE (alternative-MAZE) randomized, pivotal clinical trial evaluating the use of the LARIAT device for catheter-based, non-implant left atrial appendage closure (LAAC) as an adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation (AFib).